Concourse Financial Group Securities’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-515
| Closed | -$47K | – | 8469 |
|
|
2024
Q4 | $47K | Hold |
515
| – | – | ﹤0.01% | 1241 |
|
|
2024
Q3 | $50.9K | Hold |
515
| – | – | ﹤0.01% | 1179 |
|
|
2024
Q2 | $47.7K | Buy |
515
+22
| +4% | +$2.04K | ﹤0.01% | 1190 |
|
|
2024
Q1 | $46.8K | Sell |
493
-165
| -25% | -$15.7K | ﹤0.01% | 1208 |
|
|
2023
Q4 | $58.8K | Buy |
658
+115
| +21% | +$10.3K | ﹤0.01% | 1082 |
|
|
2023
Q3 | $39.6K | Hold |
543
| – | – | ﹤0.01% | 1166 |
|
|
2023
Q2 | $45.2K | Sell |
543
-90
| -14% | -$7.49K | ﹤0.01% | 1132 |
|
|
2023
Q1 | $48.2K | Hold |
633
| – | – | ﹤0.01% | 1108 |
|
|
2022
Q4 | $52.5K | Hold |
633
| – | – | ﹤0.01% | 1049 |
|
|
2022
Q3 | $50K | Hold |
633
| – | – | ﹤0.01% | 946 |
|
|
2022
Q2 | $47K | Sell |
633
-275
| -30% | -$20.4K | ﹤0.01% | 1121 |
|
|
2022
Q1 | $82K | Buy |
908
+67
| +8% | +$6.05K | 0.01% | 944 |
|
|
2021
Q4 | $94K | Sell |
841
-18
| -2% | -$2.01K | 0.01% | 1030 |
|
|
2021
Q3 | $108K | Sell |
859
-213
| -20% | -$26.8K | 0.01% | 952 |
|
|
2021
Q2 | $145K | Sell |
1,072
-34,325
| -97% | -$4.64M | 0.01% | 829 |
|
|
2021
Q1 | $4.8M | Sell |
35,397
-2,706
| -7% | -$367K | 0.34% | 64 |
|
|
2020
Q4 | $5.36M | Buy |
38,103
+917
| +2% | +$129K | 0.4% | 53 |
|
|
2020
Q3 | $4.14M | Buy |
37,186
+36,160
| +3,524% | +$4.03M | 0.36% | 59 |
|
|
2020
Q2 | $115K | Buy |
1,026
+15
| +1% | +$1.68K | 0.01% | 686 |
|
|
2020
Q1 | $78K | Buy |
1,011
+30
| +3% | +$2.32K | 0.01% | 745 |
|
|
2019
Q4 | $93K | Buy |
981
+202
| +26% | +$19.2K | 0.01% | 735 |
|
|
2019
Q3 | $59K | Sell |
779
-956
| -55% | -$72.4K | 0.01% | 571 |
|
|
2019
Q2 | $152K | Buy |
1,735
+531
| +44% | +$46.5K | 0.02% | 548 |
|
|
2019
Q1 | $108K | Buy |
1,204
+523
| +77% | +$46.9K | 0.01% | 662 |
|
|
2018
Q4 | $48K | Sell |
681
-1,473
| -68% | -$104K | 0.01% | 831 |
|
|
2018
Q3 | $207K | Buy |
+2,154
| New | +$207K | 0.06% | 279 |
|